Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion
Merck & Co., Inc. is strategically positioning itself for significant growth through aggressive mergers and acquisitions, including multi-billion-dollar deals in oncology and antiviral sectors, while expanding its pipeline with over 80 Phase III trials to counter the upcoming Keytruda patent cliff in 2028 and drive long-term revenue diversification. Merck & Co., Inc., trading under the … Read more